



SIMPLE CASES AND BEYOND: DO YOU TALK OCULAR TUMORS !!!

IHAB SAAD OTHMAN, MD, FRCS

PROFESSOR, CAIRO UNIVERSITY

CHAIRMAN, EYEWORLD HOSPITAL

VICE PRESIDENT, MEACO

TFOS AMBASSADOR

CASE 1: 58 YOM
CHALAZION → SURGERY X 2SEB GL CA



TUMOR EXCISION, FROZEN SECTION CONTROL



MAJOR RECONSTRUCTION: BRIDGE FLAP





CASE 2:
64 YOM, EXCISION OF UL TARSAL MASS
CONJUNCTO-PALPEBRAL MALIGNANCY



IDENTIFY TUMOR EXTENT



TUMERECTOMY -----CRYOTHERAPY



CRYO DOUBLE FREEZE THAW.....BRACHYTHERAPY



1 MONTH 18 MONTHS



36 MONTHS



RADIATION TYPES

- **Alfa particles: positive electrical charges (helium/proton)**
- **Beta particles: negative charges**
- **Gamma rays: no electrons:**
 - Gamma rays are similar to x-rays, but gamma rays originate in the atomic nucleus and x-rays from the peripheral electrons.


- **The major goal of radiation:**

- Arresting cell mitoses by interfering with DNA synthesis
- Destroy the reproductive integrity of a neoplasm



- **The tissue destruction by ionizing radiation is accomplished by free radicals.**

- **Teletherapy:**
 - Remote distance delivery
- **Brachytherapy:**
 - Near distance delivery




Isotope	Half-life	Type of radiation	Energy	Half-value layer	10% energy transmission opposite side mm{	Advantages	Disadvantages
Cobalt 60	5.26 years	Gamma	1.17, 1.33 MeV	11 lead	lead 25	Long half- life Good tissue penetration	High energy restricts shielding from personnel
Iodine 125	60.2 days	Gamma	27-35 KeV	0.025 lead	lead 0.09	Easy to shield, appropriate tissue penetration, seeds permit individualized .plaque design	Shorter half-life
Palladium 103	17 days	Gamma	21 KeV	0.008 lead	lead 0.5	.As Iodine Higher dose rate may be radiobiologically beneficial	Very short half-life
Iridium 192	74.2 days	Gamma	0.38 MeV	lead 2.7	Lead 18	Good tissue penetration ,ease in customizing plaque design.	Easier to shield than Co , but not as easy as the others
Gold 198	3 days	Gamma	0.420 MeV	lead 5	lead 2	Good energy	Short half-life
Ruthenium 106	366 days	Beta	3.5 Mev	lead 0.7	lead 1	Easily shielded, sharper dose falloff	Can only be used for thinner tumors(5 mm or less)due to limited tissue penetration

MALIGNANT EYELID EPITHELIAL TUMORS

Basal Cell Carcinoma

- Malignant cutaneous tumor arising from:
 - Basal layer of epidermis
 - Primary epithelial germ cells (pleuripotential embryonal cells) in the deepest layer of epidermis
- Aetiology:
 - >90% of eyelid malignancy
 - Related to sun-exposure in:
 - Fair complexion skin
 - Middle age or elderly
 - Distribution:
 - LL: 55%
 - Medial canthus: 30%
 - UL: 10%
 - Lateral canthus: 5%



- **Basal Cell Carcinoma**

- Behavior:
 - Locally invasive
 - Does not metastasize



Types:

- **Nodular/ Noduloulcerative type:**

- Well defined elevated, firm erythematous nodule
 - Central crater or ulcer,
 - Tumor is locally invasive
 - Madarosis
 - Ulcerative:
 - Rodent ulcer: slowly enlarges with minimal scar formation
 - Borders: beaded, pearly, shiny and rolled-in
 - Base: indurated
 - Surface: pink, granular, and covered with a crust





RODENT ULCER

- C- Eroding the orbit
 - Tumor totally erodes, eyelids, eyeglobe and orbital soft tissue and orbital bone leaving a large defect.



CASE 3: DIFFUSE CIN, CORNEAL INVOLVEMENT AT 270°





NON-SURGICAL TOPICAL THERAPY OF CONJUNCTIVAL TUMORS:

IHAB SAAD MAHMOUD OTHMAN, MD, FRCS
PROFESSOR OF OPHTHALMOLOGY
CAIRO UNIVERSITY
DIRECTOR, EYEWORLD HOSPITAL, GIZA, EGYPT

OCULAR SURFACE SQUAMOUS NEOPLASIA (OSSN)

- Premalignant and malignant alterations in the epithelium of conjunctiva or cornea
- **Various terms in literature:**
 - Squamous cell carcinoma
 - Conjunctival intraepithelial neoplasia
 - Conjunctival dysplasia
 - Ocular surface epithelial dysplasia
 - Conjunctival squamous intraepithelial neoplasia
- **Classic presentation**
 - Adult
 - Caucasian males
 - Excessive sun exposure


OSSN



- **Predisposing factors**
 - Cigarette smoking
 - Radiation exposure
 - Eczema
 - Systemic immune suppression
 - Organ transplantation
 - HIV
 - Xeroderma pigmentosum
- **Reported in pts with**
 - Autoimmune disease
 - Degenerative
 - Traumatic
 - Toxic conditions

CASE 4: 70 YOF. OSSN



UBM





HISOLOGIC SURPRISE: RESIDUAL CIN/SCCA



ADJUVANT THERAPY: WHY AND WHEN

Pathology	Type	Treatment
Resection edge positive	Dsyplasia or CIN	Observation or topical chemotherapy
Resection edge positive	Invasive SCC	Re-excision
Resection base positive	Localized	Cryotherapy
Resection base positive	Diffuse	Plaque brachytherapy
	Patient prone to recurrence	Immuno-modulation


Honavar 2019

PRINCIPLES OF MANAGEMENT

- Identify extent (edge)
- Test motility
- Provisional diagnosis
- Investigations
- Have a clear plan about management

IDENTIFY EXTENT (EDGE)

- Fluorescein stain
- Rose Bengal stain



ASSESS THE BASE: UBM: CORRELATES WITH PATHOLOGY




TEST MOTILITY



ASSESS EXTENT: CT/MRI

- Recurrent inferior fornix SCC:



CASE 5

- 68 YOM
- Epibulbar mass x 1 year



EXTENSIVE LESIONS





CILIARY BODY MELANOMA: THE TIP OF THE ICEBERG




RING MELANOMA: ENUCLEATE



SAD STORY: CATARACT EXTRACTION



CASE 6 : 14 YOM, LOSS OF VISION OD



Ultrasound Report
Date: 22-11-2018

A,B scan of Rt eye revealed somolucnet vitreous cavity, highly echogenic thick membranous echo in the inferior globe, continuous with the retina at the optic disc (inferior RD).
Optic nerve and choroidal shadow are within normal

Impression
Rt inferior RD. (mostly Exudative RD)



PPV

CASE 6: 14 YOM



AFTER 2 CYCLES OF CHEMO

Necrotic retinoblastoma
Massive choroidal invasion
EOE



Diagnosis :
Epibulbar mass with peribulbar and intra-ocular infiltration, Enucleation,
RETINOBLASTOMA POORLY DIFFERENTIATED WITH SIGNIFICANT EXTRA-OCULAR
EXTENSION, FREE SURGICAL AND OPTIC NERVE MARGINS, p T4.

Elia
11/4/2017

ANTERIOR SEGMENT SILENT MISLEADERS:


- Older age at presentation
- Flat retinal pattern
- Good visual acuity



- 6 YOF
- Cataract surgery 9 months ago
- Epibulbar mass
- Refusal of enucleation for 3 months



- Extensive endophytic retinoblastoma
- Massive optic nerve and extraocular extension
- Further management:
 - Chemotherapy x 9 cycles
 - EBRT
 - Intrathecal MX



RETINOBLASTOMA

- **Diagnosis:**

- **History:**

- Leucocoria, Strabismus
- Rule out familial cases
- Differentiate a case of leucocoria



RETINOBLASTOMA

- **Diagnosis:**
- **Clinical presentation**


- **Leukocoria:** 90%
- **Strabismus:** 35%
- **Golden Rule 1:**
 - **Any child with strabismus should have a dilated fundus examination**



RETINOBLASTOMA

- Fixed dilated pupil
- Neovascular glaucoma
- Heterochromia

- Hyphema:
 - **Golden Rule 2**
 - *Spontaneous hyphema and unilateral buphthalmos in a child should be considered retinoblastoma until proven otherwise*



RETINOBLASTOMA

- **Pseudoinflammatory presentations:**
 - **Pseudohypopyon**
 - **Golden rule 3:**
 - *Any Childhood intraocular inflammation should be considered retinoblastoma until proven otherwise*
 - **Orbital cellulitis-like picture (tumor necrosis)**
 - **Golden Rule 4:**
 - **CT is a must in orbital cellulitis suspect. Look for intraocular mass**



SYSTEMIC CHEMOTHERAPY

DOES NOT WORK ALONE !!!

CASE 7: OCULODERMAL MELANOCYTOSIS (N OF OTA)

Benign pigmented lesion arising from dermal melanocytes

- Pathology:
 - Congenital periocular flat cutaneous pigmentation
 - Associated epibulbar and uveal pigmentation
- 45 YOM
- Nevus of Ota
- Recent diminution of vision OS



- **Prognosis:**

- 0.4% develop uveal melanoma
- Slightly more risk of brain and orbital melanoma
- Eyelid, conjunctival melanoma are extremely rare



Courtesy A. ElHusseiny

CASE 8: CAUGHT BY SURPRISE


- 28 YOM
- Dx: RRD
- Emergency PPV , SO, endolaser


Do not :

- Drain Subretinal fluid
- Do laser
- Put silicone oil


Do:

- A simple vitrectomy and leave as it is





**PARTIAL LAMELLAR RESECTION+
BRACHYTHERAPY: LOCAL CONTROL**



DOM 12 months

CASE 9: 60 YOM, UVEAL MELANOMA; PLSU



ORBITAL VASCULAR LESIONS

- 6 to 12 % of all orbital neoplasms
- Vascular hamartomatous lesions:
 - Cavernous hemangioma
 - Capillary hemangioma
 - Cavernous lymphangioma
- Orbital varix
- Hemangiopericytoma
- Angiosarcoma
- Intravascular papillary endothelial hyperplasia
- A/v fistula
- vascular leiomyoma,
- angiolymphoid hyperplasia with eosinophilia
- Kimura disease

B BLOCKERS: PROPRANOLOL

2 mk/kg x 4 months




Courtesy Léauté-Labrèze, Bordeaux, France

CASE 10; 4 MONTH OLD BOY

- Early treatment is preferred
- Prolonged therapy may be necessary (3-4 months)









BORN WITH 2 HEADS

CASE 12: 16 DAY OLD FEMALE



MRI







calcification were present.

Microscopic :

Sections examined from the specimen received revealed squamous epithelium, respiratory epithelium, gut mucosa, smooth muscle bundles, lymphoid aggregates, skin adnexa, mature cartilage, mature bone, brown fat, nerve bundles, mature ganglia, adrenal tissue, glial tissue with foci of immature cartilage, immature nephroblastic and neuroepithelium in less than three low power fields

All surgical margins are free.

Diagnosis :

Right eye exantration, IMMATURE TERATOMA, GRADE II, ALL SURGICAL MARGINS ARE FREE.

Prof. Dr. Elia Anis Ishak

Prof. Dr. Elia Anis Ishak




THE GUIDE
in Ophthalmic Practice

Part 1
Ophthalmic Oncology Guidelines

Ihab Saad Othman
Hesham Mohamed Ghariab

EYE ACADEMY



REMEMBER TO



LIVE IN STYLE



ihabsaad@hotmail.com